news
Combatting T-cell tumours with antibody drug conjugates
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
List view / Grid view
Cancer research
news
Reversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
news
MUTYH variants implicated in a broader range of cancers
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
podcasts
Breaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
news
The first core regulatory circuit identified for ALCL
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
news
New strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
news
The mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
news
Exact bacterial lineage associated with colorectal cancer pinpointed
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
news
Potential for personalised, molecularly guided UTUC treatments
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
article
Optimised antibody panels for CTC and rare cell enumeration
Despite significant strides in cancer research, metastasis remains the primary cause of cancer-related mortality globally. Joby Chesnick and Tracey Long, from the Digital Biology Group and Life Science Group, respectively, at BioRad Laboratories, reveal how investigation into circulating tumour cells (CTCs) and other rare cell types has led to the…
news
New link between FBXW7 mutations and EGFR signalling identified
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
news
Targeting cancer cells in early hypoxia
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
news
Targeting Inc-HLX-2-7 shrinks group 3 medulloblastoma tumours
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
news
P47 suppresses metastasis of HER2-positive breast cancer
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
